Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma

导出原文传递

翻译打印收藏纠错

作者： Kuroda, Takafumi ^[1] ; Ogiwara, Hideaki ^[2] ; Sasaki, Mariko ^[3] ; Takahashi, Kazuaki ^[4] ; Yoshida, Hiroshi ^[5] ; Kiyokawa, Takako ^[6] ; Sudo, Kazuki ^[7] ; Tamura, Kenji ; Kato, Tomoyasu ; Okamoto, Aikou ; Kohno, Takashi

作者单位： Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan ^[1] Natl Canc Ctr, Dept Gynecol, Tokyo, Japan ^[2] Jikei Univ, Sch Med, Dept Pathol, Tokyo, Japan ^[3] Natl Canc Ctr, Res Inst, Div Canc Therapeut, Tokyo, Japan ^[4] Dept Breast & Med Oncol, Tokyo, Japan ^[5] Natl Canc Ctr, Div Genome Biol, Res Inst, Tokyo, Japan ^[6] Jikei Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan ^[7]

关键词 ARIDIA Ovarian clear cell carcinoma (OCCC)Gemcitabine Precision medicine Predictive biomarker

发布时间 2020-06-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交